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Brief description of the impact and novelty of this study: 
This to date largest study on the topic tries to settle the question of the significance of 
EPCAM as a molecular marker in RCC. We found EPCAM independently associated with 
adverse pathological findings and worse overall survival. Even in the group of localized and 
low-grade tumors, EPCAM proved its value as an independent prognostic marker. For the 
first time, we are demonstrating a raise of predictive accuracy by the information of EPCAM 
protein expression.  
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Abstract: 
Epithelial cell adhesion molecule (EPCAM) has recently attained a renewed interest as a 
candidate protein in diagnosis, prognostication and therapy of various tumor entities. The 
molecular epidemiology and prognostic relevance of EPCAM in renal cell carcinoma (RCC) 
and amongst the histological subtypes of RCC is unclear.  
We analyzed the prevalence and prognostic significance of EPCAM in a tumor tissue micro-
array (TMA) composed of 1088 independent RCCs samples by immunohistochemistry (IHC). 
We found significant variations of EPCAM IHC staining intensities in between the RCC 
subtypes: In papillary and chromophobe RCC, the majority of tumors (89-93%) showed an at 
least weak EPCAM protein expression. In the largest subgroup, the clear cell (cc)RCC 
(n=767), a negative EPCAM IHC was found in 1/3 of the patients and was associated with 
high-grade disease and nodal metastases. Kaplan-Meier analyses demonstrated a 
significant association between positive EPCAM IHC and prolonged overall survival, even in 
a subset of low risk ccRCC.  
In multivariable analyses, EPCAM represented an independent risk factor of survival 
throughout all subgroups. For localized, low-grade ccRCC, information of EPCAM IHC raised 
predictive accuracy of a multivariate model by ~5%, compared to T-stage and grade alone.  
Our findings indicate, that EPCAM is an independent prognostic molecular marker in ccRCC 
and, especially in localized ccRCC, might be able to provide auxiliary information for a better 
prognostication. 
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Introduction 
Today, the majority of diagnosed and treated renal cell carcinomas (RCC) represent 
early stage tumors, assuming a high cure probability after localized therapy. Counter-
intuitively, the cancer-specific mortality rates have been rising over the last decades 
displaying RCC’s rather unpredictable nature of disease1. Specifically, even in small, 
low stage tumors, a well acknowledged risk of meta- and synchronous metastatic 
disease is described2, 3. The current version of the EAU guidelines on RCC 
recommends risk-adapted follow-up schemes after curative treatment, based on 
TNM classification and Fuhrman grade. There is no general recommendation for 
integrated prognostic systems or nomograms. Molecular markers are currently not 
recommended at all, since none of the described markers has been shown to 
improve predictive accuracy4. Yet, aside from diverse risk-stratification tools based 
on clinicopathologic variables, great hope is set on molecular markers to improve 
customization of patients´ individual prognostication5. Similar to breast- and colon 
cancer, there is an ongoing debate on the significance of molecular markers to better 
stratify patients in prognostic subgroups or to trigger potential adjuvant treatment 
modalities for RCC6-8. 
Epithelial cell adhesion molecule (EPCAM) is a frequently detected marker in (pre-) 
malignancies of various tissues9. In fact, EPCAM was not only the first human tumor 
antigen identified10, but also the target of the first monoclonal antibody (mAB) therapy 
used in clinical oncology11. It is broadly overexpressed in premalignant lesions and 
carcinomas of various origins, such as prostate and bladder, ovarian, lung, colon and 
breast cancers12. Thus, EPCAM IHC is widely used to discriminate neoplasia of 
epithelial and non-epithelial origin and for the detection and characterization of 
circulating tumor cells (CTCs)12, 13.  
Page 3 of 26
John Wiley & Sons, Inc.
International Journal of Cancer
  4
 
Controversy persists, whether EPCAM represents a valuable prognostic marker in 
RCC. While some studies describe an association of loss of EPCAM expression with 
adverse tumor characteristics and a negative correlation with survival in at least 
univariant analysis14, 15, other reports could not support the predictive value of 
EPCAM protein expression16, 17.  
To address this debate, the aim of this study was to investigate the prevalence and 
prognostic significance of EPCAM in a large European RCC cohort, using a renal 
tumor tissue microarray (TMA) including a total of 1088 different tumor samples. 
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Materials and Methods 
Tissue microarray (TMA)  
A previously described RCC TMA18 was used, containing tumor samples from 585 
patients operated at the University Medical Center Hamburg Eppendorf (1991-2007) 
and from 503 patients treated at the University Hospital Basel (1970-1994) due to 
suspected RCC. The tumors were graded according to the grading system published 
by Fuhrman et al.19 and were staged according to the 5th (Basel) and 6th (Hamburg) 
TNM classification 20 21. The pT1a and pT1b subclassifications were combined in a 
global pT1-group, analog the 1997 version. H&E stained histological sections from all 
paraffin-embedded specimens were reviewed and the tumors were marked on the 
slides. One 0.6 mm tissue core was punched out from the index area, and 
transferred into a tissue microarray (TMA) format as previously described by 
Kononen et al.22. 
Clinical data and follow up  
Clinical features (age at time of operation, gender, diagnosis, staging, histological 
subtype, TNM-stage, grading) were extracted from institutional databases. In case of 
missing or incoherent values, the corresponding patient charts were retrospectively 
analyzed, whenever possible.   
Follow-up (F/U) data was obtained in accordance with local laws and acquired either 
from institutional databases or by a standardized postal survey sent to the referring 
physician or the patient. 
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Immunohistochemistry (IHC) 
Freshly cut TMA sections were stained on one day in a single experiment. High-
temperature pretreatment of slides was done in a pressure cooker (pH 6.1 (DAKO 
buffer, S1699) for 20 minutes. IHC was performed using a monoclonal antibody 
(1:10, clone VU-1D9, Novocastra, UK) to detect the membrane bound positivity for 
EPCAM protein. 
The Envision system® (DAKO, Glostrup, Denmark) was used to visualize the IHC.  
Staining intensities and percentages of positive tumor cells were recorded for each 
tissue spot by a single pathologist (G.S.). A 4-staged score (0, 1+, 2+, 3+) was 
deducted from these two parameters according to a previously described scheme17, 
18.  
Statistical analysis 
For statistical analyses, EPCAM staining was dichotomized into two groups (negative 
(score 0) vs. positive staining (score 1+, 2+ and 3+). Frequencies of EPCAM staining 
intensities were analyzed in renal tumors of various histologic subtypes.  
In ccRCC the staining intensity of EPCAM was compared to Fuhrman grade, pT-
stage, pN-stage (pN0/X vs. pN1/2), and to the absence or presence of synchronous 
metastases (cM0 vs. cM1). The 2-sided chi-square test was used for comparison of 
proportions. 
The Kaplan-Meier (KM) method was used to explore the prognostic significance of 
EPCAM staining predicting overall (OS) and cancer-specific survival (CSS) using the 
log-rank test. The effect of EPCAM staining on survival was evaluated in a 
multivariate Cox regression model. The concordance (C-) index, which represents 
the area under the curve adapted for survival data, was determined to estimate and 
compare the predictive accuracy of multivariate models. The C-index was bias- 
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corrected by using 200 bootstrap resamples. S-PLUS Professional, version 1 
(MathSoft Inc., Seattle, USA) and Statistical Package for the Social Sciences (SPSS) 
v.12.0 (SPSS Inc., Chicago, USA) were applied. All tests were two-sided with a 
significance level at 0.05. 
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Results 
Patients and EPCAM Immunohistochemistry 
A total of 916 of 1088 tumors were evaluable by EPCAM-IHC. Non-informative cases 
were either caused by missing tissue on the TMA or absence of unequivocal tumor 
cells on TMA spots. EpCam immuonstaining was predominantly membranous. 
Although cytoplasmatic staining was seen, this was nearly always associated with a 
strong membranous staining. In normal kidney tissue, a strong cytoplasmatic and 
membranous staining was found in proximal tubular cells. 
Among the different RCC subgroups, negative EPCAM expression was significantly 
more often observed in clear cell carcinomas (ccRCC) than in other histological 
subtypes of chromophobe (ch)RCC, papillary (pap)RCC and oncocytoma (34% vs. 7-
11%; p<0.001; Fig.1). As non-ccRCC tumors did not prove a sufficient statistical 
power due to the low frequency of negative stained cases, all further calculations 
were performed within the subgroup of ccRCC (n=767). The pathological and follow-
up data of the ccRCC-group is summarized in Table 1. The median age at the time of 
operation was 62 years (range: 15-88), 65% of the ccRCC patients were of male 
gender. 
Association analysis demonstrated that a negative EPCAM staining significantly 
correlated with a higher Fuhrman grade (p=0.005) and with node positive tumors 
(p=0.018; Fig. 2). No significant level was reached for the pT-stage and distant 
metastasis (M1, p=0.230, not shown in Fig. 2). 
Survival analyses, all ccRCC 
Age (p<0.001), but not gender (p=0.449), was associated with overall survival in 
univariate Cox regression analyses. Further, the pTNM stage information and the 
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Fuhrman grade significantly correlated with OS as determined by Kaplan-Meier 
analysis (all p<0.001; curves not shown), as did EPCAM expression in the 
categorized (p=0.001) and the 4-staged model (p=0.014; curves not shown). Figure 
3a depicts the Kaplan-Meier curves per dichotomized EPCAM expression for a 
subset of cases, in which full information for multivariate Cox regression analysis was 
available (n=441). 
For the analysis of CSS, the specific nature of death could be confirmed in 78 out of 
249 deceased patients (Tab.1). In 171 cases the specific nature of death could not 
be determined reliably. In univariate Cox regression analyses, only pT stage 
(p<0.001), but not Fuhrman grade (p=0.292), pN-status (p=0.056) or EPCAM IHC 
(p=0.207) achieved significant levels. With the low numbers of confirmed cancer-
specific deaths apparently fading the statistical power, further calculations regarding 
the endpoint CSS had to be omitted.  
In a multivariate Cox-proportional hazard model, including nodal positive (pN+) and 
synchronously metastatic (M1) cases, EPCAM and all other analyzed factors in the 
model achieved independent predictor status of OS aside from age (all p<0.05; 
complete data set available in n=441 patients; Tab. 2a). The same was observed 
when the dichotomized EPCAM IHC information was substituted by the 4-staged 
variable (p=0.044; data not shown in Tab. 2a). 
Non-metastatic tumors  
To assess the predictive value of EPCAM IHC in non-metastatic RCC, we selected a 
subgroup of patients (n=389), excluding cases with synchronous nodal (pN1/2) or 
distant metastasis (M1) at the time of surgery. In this subgroup the EPCAM protein 
expression (dichotomized and 4-staged), pT-stage, Fuhrman grade, and age were all 
independent predictors of OS as determined by multivariate analysis in a Cox-
proportional Hazard model (all p<0.05; Tab. 2b for dichotomized EPCAM). 
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To additionally asses the relative impact provided by the EPCAM IHC, the 
concordance indices (c-index) of multivariate analyses were compared; the addition 
of EPCAM IHC did not significantly raise predictive accuracy of a basic model 
consisting of pT-stage and Fuhrman grade (<1%; 0.6768 vs. 0.6687).  
Low/ intermediate risk tumors 
A subgroup (n=217) analysis of presumably low/ intermediate risk tumors, excluding 
high grade (G3/4), pT4, pN+, or M+ cases, was calculated. On univariate analyses, 
both the dichotomized (p=0.004; Fig. 3b) and the 4-staged (p=0.026) EPCAM IHC 
categories and Fuhrman grade (p=0.041) significantly predicted overall survival, 
while pT-stage (p=0.066) did not. 
On multivariate analysis including age, pT-stage and grading, younger age and a 
positive EPCAM expression independently predicted a more favorable OS, while pT-
stage and Fuhrman grade did not (Table 2c). 
In this subgroup, the addition of dichotomized EPCAM staining into a predictive 
model, consisting of pT-stage and Fuhrman grade (c-index: 0.5805), resulted in a 
5.6% increase of predictive accuracy (c-index: 0.6365). 
Low risk tumors analog to UISS 
Analog to the histopathological definitions of the UISS risk group stratification by 
Zisman et al.23, a low risk subgroup of ccRCC patients (n=138) with pT1 and 
Fuhrman Grad 1 or 2 only was selected. As information of the preoperative ECOG-
Status was missing, we had to assume all patients to have been in a favorable 
condition (ECOG=0). Consequently, we were not able to further assess the gain of 
predictive accuracy by incorporation of EPCAM IHC results within the originally 
defined group.  
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In this low risk group, EPCAM IHC (p=0.023) but not Fuhrman grade (p=0.184) was a 
predictor for OS in univariate Cox regression analyses. The 5-year-survival rates for 
the EPCAM positive and negative group were 85% (standard deviation (SD): 4.6%) 
and 64% (SD: 8.9%), respectively. The Kaplan-Meier estimates of survival according 
to dichotomized EPCAM IHC are depicted in Figure 3c. Of note, there was no 
significant difference regarding the distribution of age between both groups (Mann-
Whitney U test: p=0.126) 
  
Discussion 
The transmembranous glycoprotein EPCAM – also CD326 – is commonly recognized 
as a cell-cell-adhesion molecule in normal epithelial tissue. However, recent research 
revealed that EPCAM is substantially integrated in the processes of cell migration-, 
differentiation- and proliferation24, 25. Here, the activation of the EPCAM glycoprotein 
leads to intramembranous proteolysis with the release of the intracellular domain 
(“EpICD”). A nuclear translocation of EpICD forms a multiprotein signaling-complex25. 
With a siRNA-induced down-regulation of EPCAM resulting in a decreased cell 
proliferation, mitogenic influence of this molecule has been further proven26.  
Though, the results of the EPCAM protein expression as a prognostic marker are 
ambiguous: An overexpression of EPCAM in prostate and ovarian cancer is 
correlated to a worsen survival27, 28, and EPCAM siRNA treatment decreased cell 
migration and invasion by over 90% in breast cancer cells26. On the other hand, loss 
of EPCAM expression in colorectal cancer is associated with the development of 
metastases and local recurrence29. These ambivalent correlations might be due to 
the multifaceted functions of EPCAM and the multiple pathways involved in EPCAM 
signaling: On the one side, overexpression of EPCAM results in an up-regulation of 
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the proto-oncogene c-myc, an elevated metabolic activity and a raised capacity for 
colony formation, which positively links EPCAM-expression to cell cycle deregulation 
and proliferation30. On the other side, loss of EPCAM is associated with nuclear beta-
catenin localization, a reduced cell-cell adhesion, an increased migratory potential 
and tumor budding in colorectal carcinomas29. 
For RCC the characteristics of EPCAM expression or its loss still have to be defined, 
as well as the potential role as a prognostic marker.  
In analogy to previous studies, we observed significant differences of the EPCAM 
protein expression between the RCC entities. Especially the chromophobe subtype 
seems to be characterized by high percentages of EPCAM positive cells, as found in 
previous (87%17; 100%15; 100%31) and in our study (93%). Since this result in chRCC 
is in contrast to findings in oncocytomas, Liu et al. suggested that EPCAM-IHC might 
serve as a differentiator between these entities, which are sometimes hard to 
distinguish for the pathologist31.  
The predominant group of RCC is composed by ccRCC. For this subtype, Seligson 
et al. reported a positive correlation between EPCAM expression and low stage and 
localized diseases15. Went et al. could not confirm such a significant correlation, but 
they described metastatic ccRCC tissue to be significantly less often positive for 
EPCAM, when compared to the respective primary tumors17. Our study demonstrates 
a significant correlation between low grade and node negative tumors with a positive 
EPCAM-IHC. In summary, it appears that EPCAM expression is a favorable feature 
in ccRCC, similar to the findings reported for colorectal carcinomas29.  
This assumption is corroborated by our and previous findings on EPCAM and 
prognosis: In a series of 193 localized tumors with unreported histologic subtypes, 
Shvarts et al. described EPCAM to be a predictor of tumor progression as evaluated 
by univariate analysis14. Seligson et al. reported a significant correlation between 
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EPCAM positivity and CSS for ccRCC, both in uni- and multivariate analyses 
(n=318)15. This group also investigated 150 metastatic ccRCC resected prior to 
immunotherapy, but the trend for a prolonged survival in tumors expressing EPCAM 
was not statistically significant32. Went et al. could not confirm independent predictor 
status of EPCAM in IHC of 96 patients, although tumors expressing EPCAM had a 
trend toward a better survival17.   
Our KM-analyses demonstrate a positive EPCAM status to be significantly correlated 
with a longer survival. We were able to validate the independent predictor status of 
EPCAM IHC both in a 4-staged, as well as in a, clinically more practical, 
dichotomized scoring system. This was especially true for the low (I/II) grade, non-
systemic tumors, where EPCAM was the only independent tumor associated factor 
on multivariate analyses corrected for stage and grade. For this group of patients, 
which comprises nowadays a large fraction of RCC patients, prognostication is 
particularly difficult. In our study, the addition of EPCAM raised the predictive 
accuracy by 4.7% compared to the combination of stage and grade alone. For 
comparison only, the recently much-noticed prostate cancer gene 3 (PCA3) raises 
predictive accuracy of a standard biopsy nomogram by 2.3-4.6%33.  
The major limitations of our study are the retrospective design and the lack of 
sufficient data regarding the specific nature of death, which limits our analyses to the 
endpoint overall survival. However, as shown in our multivariate analyses, the 
prognostic significance of EPCAM protein expression was independent of patients’ 
age. Further, the vast majority of the here reported patients were diagnosed years 
before todays standard therapies for metastatic RCC with multikinase- and m-Tor-
inhibitors became available.  
The here for the first time described raise of predictive value should be further 
confirmed in a prospective manner. If confirmed, we suppose this would be an 
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important step towards the implementation of molecular markers, such as EPCAM, 
for a more personalized patient prognostication and an individualized follow-up 
recommendation.  
 
Conclusion 
In this large TMA-based study the significant prognostic value of EPCAM in RCC was 
validated. Beside the differences of EPCAM expression in the RCC subgroups, a 
significant correlation between EPCAM expression and favorable tumor features was 
shown for ccRCC. This also reflects the individual patients’ prognosis, with EPCAM 
being an independent predictor of survival, especially in localized diseases of 
ccRCC.  
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Figure legends 
Table 1: Description of the histopathological features and follow up data of the 
clear cell RCC subgroup 
Table 2a-c: Multivariate analyses: prediction of overall survival for all (a), non-
metastatic (b) and low/ intermediate risk (c) ccRCC 
Figure 1:  Frequencies of EPCAM staining intensities in the 4 largest renal tumor 
subgroup  
Figure 2: Percentages of EPCAM staining intensities in the ccRCC subtype, 
stratified for pT-stage, nodal status and grade  
Figure 3a-c: Kaplan-Meier estimates of overall survival per dichotomized EPCAM 
IHC:  a) all ccRCC;  b) intermediate/low risk ccRCC subgroup, excluding 
pT4, G III/ IV, pN+, or M1 cases; c) analog low risk (UISS) ccRCC 
subgroup  
Picture 1a-d: Samples of negative (a), weak (b), moderate (c) and strong (d) stained 
EPCAM IHC spots 
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ccRCC on TMA (n=767) n % 
pT pT1 328 42,8 
pT2 96 12,5 
pT3 331 43,2 
pT4 9 1,2 
pTx 3 0,4 
  
pN pN0 280 36,5 
pN1/2 46 6,0 
pNx 441 57,5 
  
M status cM0 715 93,2 
cM+ 52 6,8 
  
Fuhrman grade G1 118 15,4 
G2 280 36,5 
G3 188 24,5 
G4 96 12,5 
n.a. 85 11,1 
  
EPCAM dichotomized negative 221 28,8 
any staining intensity (+-+++) 436 56,8 
n.a. 110 14,3 
  
EPCAM staining negative (-) 221 28,8 
weak (+) 103 13,4 
moderate (++) 98 12,8 
strong (+++) 235 30,6 
n.a. 110 14,3 
  
Follow up (F/U) status dead 249 32,5 
   cancer specific death 66 26,5 
   other cause of death 12 4,8 
   uncertain cause of death 171 68,7 
alive 304 39,6 
no F/U 214 27,9 
median/ mean F/U (months) 34/52 (0.2-354m) 
 
 
Table 1: Description of the histopathological features and follow up data of the clear cell RCC subgroup 
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 a) uni- and multivariate analyses: all ccRCC (n=441) 
 univariate analysis multivariate analysis 
 
p-value 
hazard 
ratio 
95% confidence interval 
p-value 
hazard 
ratio 
95% confidence interval 
lower upper lower upper 
Age < 0.001 1.025 1.012 1.038 < 0.001 1.028 1.014 1.041 
pT stage < 0.001    0.022    
pT 2 vs. 1 0.044 1.589 1.012 2.496 0.074 1.533 0.959 2.452 
pT 3 vs. 1 < 0.001 2.346 1.681 3.275 0.005 1.673 1.170 2.393 
pT 4 vs. 1 < 0.001 4.611 2.087 10.188 0.036 2.475 1.061 5.778 
pN status < 0.001    < 0.001    
pN1 vs. pN0 < 0.001 4.946 2.915 8.395 < 0.001 3.171 1.825 5.510 
pNx vs. pN0 0.007 1.581 1.133 2.204 0.053 1.409 0.996 1.994 
cM1 vs. cM0 0.002 2.246 1.339 3.769 0.004 2.244 1.301 3.873 
Fuhrman grade < 0.001    < 0.001    
Fuhrman 2 vs. 1 0.040 1.869 1.028 3.400 0.287 1.396 0.755 2.579 
Fuhrman 3 vs. 1 0.001 2.742 1.520 4.948 0.054 1.864 0.989 3.512 
Fuhrman 4 vs. 1 < 0.001 6.167 3.347 11.36 < 0.001 3.977 2.071 7.635 
EPCAM IHC pos. vs. neg. 0.001 0.640 0.486 0.843 0.022 0.718 0.541 0.953 
 
b) uni- and multivariate analyses: non-metastatic ccRCC (n=389) 
 univariate analysis multivariate analysis 
 
p-value 
hazard 
ratio 
95% confidence interval 
p-value 
hazard 
ratio 
95% confidence interval 
lower upper lower upper 
Age < 0.001 1.028 1.013 1.042 < 0.001 1.029 1.014 1.044 
pT stage < 0.001    0.005    
pT 2 vs. 1 0.031 1.719 1.051 2.809 0.014 1.892 1.140 3.139 
pT 3/4 vs. 1 < 0.001 2.433 1.699 3.482 0.002 1.846 1.256 2.713 
Fuhrman grade < 0.001    < 0.001    
Fuhrman 2 vs. 1 0.036 2.062 1.048 4.058 0.094 1.797 0.905 3.569 
Fuhrman 3 vs. 1 0.002 2.896 1.485 5.650 0.04 2.086 1.034 4.209 
Fuhrman 4 vs. 1 < 0.001 6.866 3.436 13.71 < 0.001 5.027 2.437 10.370 
EPCAM IHC pos. vs. neg. 0.001 0.604 0.447 0.816 0.004 0.639 0.47 0.867 
 
c) uni- and multivariate analyses: low and intermediate risk ccRCC (n=217) 
 univariate analysis multivariate analysis 
 
p-value 
hazard 
ratio 
95% confidence interval 
p-value 
hazard 
ratio 
95% confidence interval 
lower upper lower upper 
Age 0.002 1.039 1.014 1.065 0.005 1.039 1.012 1.067 
pT stage 0.066    0.103    
pT 2 vs. 1 0.749 1.133 0.527 2.435 0.216 1.679 0.739 3.817 
pT 3 vs. 1 0.023 1.870 1.092 3.203 0.038 1.809 1.033 3.169 
Fuhrman grade 2 vs. 1 0.041 2.030 1.028 4.008 0.091 1.827 0.908 3.675 
EPCAM IHC pos. vs. neg. 0.004 0.486 0.296 0.798 0.010 0.506 0.301 0.850 
 
Table 2 a-c: Multivariate analyses: prediction of overall survival for all (a). non-metastatic (b). and low/ intermediate risk (c) ccRCC 
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